Febuxostat in the management of hyperuricemia and chronic gout: a review
作者： Brian Tomlinson
DOI: 10.2147/TCRM.S3310
关键词:
摘要: … , and safety of febuxostat were investigated in a phase I study in individuals with normal (n = … The in vitro and animal studies with febuxostat showed it was more potent than allopurinol …
goutpal.com 
researchgate.net 参考文章(45)
Reza Khosravan, Brian Grabowski, Jing-Tao Wu, Nancy Joseph-Ridge, Laurent Vernillet, Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects British Journal of Clinical Pharmacology. ,vol. 65, pp. 355- 363 ,(2008) , 10.1111/J.1365-2125.2007.03016.X
S. Hoshide, Y. Takahashi, T. Ishikawa, J. Kubo, M. Tsuchimoto, K. Komoriya, I. Ohno, T. Hosoya, PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides, Nucleotides & Nucleic Acids. ,vol. 23, pp. 1117- 1118 ,(2004) , 10.1081/NCN-200027377
Ken Okamoto, Bryan T. Eger, Tomoko Nishino, Shiro Kondo, Emil F. Pai, Takeshi Nishino, An Extremely Potent Inhibitor of Xanthine Oxidoreductase CRYSTAL STRUCTURE OF THE ENZYME-INHIBITOR COMPLEX AND MECHANISM OF INHIBITION Journal of Biological Chemistry. ,vol. 278, pp. 1848- 1855 ,(2003) , 10.1074/JBC.M208307200
Robert D. Abbott, Frederick N. Brand, William B. Kannel, William P. Castelli, Gout and coronary heart disease: The framingham study☆ Journal of Clinical Epidemiology. ,vol. 41, pp. 237- 242 ,(1988) , 10.1016/0895-4356(88)90127-8
S.-I. Hung, W.-H. Chung, L.-B. Liou, C.-C. Chu, M. Lin, H.-P. Huang, Y.-L. Lin, J.-L. Lan, L.-C. Yang, H.-S. Hong, M.-J. Chen, P.-C. Lai, M.-S. Wu, C.-Y. Chu, K.-H. Wang, C.-H. Chen, C. S. J. Fann, J.-Y. Wu, Y.-T. Chen, HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 4134- 4139 ,(2005) , 10.1073/PNAS.0409500102
M. Mukoyoshi, S. Nishimura, S. Hoshide, S. Umeda, M. Kanou, K. Taniguchi, H. Muroga, In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. ,vol. 38, pp. 496- 510 ,(2008) , 10.1080/00498250801956350
Edward Roddy, Weiya Zhang, Michael Doherty, The changing epidemiology of gout. Nature Reviews Rheumatology. ,vol. 3, pp. 443- 449 ,(2007) , 10.1038/NCPRHEUM0556
Keiji Komoriya, Yoshio Osada, Masaichi Hasegawa, Hideki Horiuchi, Shiro Kondo, Ronald C. Couch, Travis B. Griffin, Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees European Journal of Pharmacology. ,vol. 250, pp. 455- 460 ,(1993) , 10.1016/0014-2999(93)90033-E
Gim Gee Teng, Raj Nair, Kenneth G Saag, Pathophysiology, clinical presentation and treatment of gout. Drugs. ,vol. 66, pp. 1547- 1563 ,(2006) , 10.2165/00003495-200666120-00002
K. Komoriya, S. Hoshide, K. Takeda, H. Kobayashi, J. Kubo, M. Tsuchimoto, T. Nakachi, H. Yamanaka, N. Kamatani, Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides, Nucleotides & Nucleic Acids. ,vol. 23, pp. 1119- 1122 ,(2004) , 10.1081/NCN-200027381